Scrip is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

Arena Rises, But Raises Questions With Phase II Ralinepag Data In PAH

Executive Summary

Arena reported statistically and "clinically" significant results from its Phase II study for ralinepag in pulmonary arterial hypertension (PAH), driving its share price up by more than 40%, but details expected later this year or in 2018 are needed to shed more light on the data.

Advertisement

Related Content

Arena To Advance GI, Derm Ambitions With $800m From United For PAH Candidate
On A Roll: Arena Continues Streak Of Positive Data With Small Crohn's Pain Study
Eisai's Obesity Drug Belviq Passes Cardiovascular Outcomes Test
Finance Watch: In Obesity, Vivus Raises Cash For Deals, Orexigen Finds A Buyer
Finance Watch: The Curious Case Of Proteostasis' Short Attack
J&J’s $30bn For Actelion Buys Immediate And Longer-Term Value
Deal Watch: Taking Care Of Business Before J.P. Morgan
United Therapeutics Expects Actelion To Add To PAH Market
Actelion's Uptravi Approval To Shake Up Market
Arena moves PAH drug forward despite Phase Ib adverse event

Topics

Related Companies

Advertisement
UsernamePublicRestriction

Register

SC099104

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel